<DOC>
	<DOCNO>NCT02787356</DOCNO>
	<brief_summary>The purpose study ( 1 ) collect train observer score digital image skin irritated generic RLD Lidocaine 5 % deliver via TDS , ( 2 ) ass performance automate system predict score directly digital image</brief_summary>
	<brief_title>Standard TDS Irritation Study : Trained Skin Grader vs. Digital Imaging</brief_title>
	<detailed_description>Subjects screen prior dose ensure subject meet inclusion exclusion criterion . The test material test simultaneously . Skin sit paraspinal region utilized application . The test sit randomize among individual subject accord assigned identification number . All patch apply removed laboratory staff . Due safety concern , recommend simultaneously apply two whole , active , Lidocaine Patch 5 % patch subject 21-day period . The optimum design study depend design test product patch . Since RLD matrix design safely cut , one-fourth patch use study . If test product patch also design cut small size , also cut one-fourth one-fourth test product patch apply simultaneously one-fourth RLD patch ( separate skin site ) . Each test article apply site skin contact period approximately 24 hour ( +/-1 hr . ) , exception weekend ( 72 hour , +/- 1 hr. ) . There visit weekend . Evaluations make removal every patch single trained grader along single digital imaging instrument . Re-applications make test site unless reaction become strong ( combination number letter grade 3 ) make unadvisable , point patch application discontinue test article .</detailed_description>
	<mesh_term>Skin Manifestations</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Males Females , age [ 1865 year old 18 year old ] Signed informed consent Good general health Subject pregnant lactating . Medical history condition would significantly influence immune response ( e.g. , primary acquire immunodeficiency , HIV positive AIDS , allergic disease , anaphylaxis , asthma generalize drug reaction , neoplasms , lymphoma leukemia , rheumatoid arthritis , systemic lupus erythematosus ) . Medical history significant dermatologic disease condition , atopy , psoriasis , vitiligo condition know alter skin appearance physiologic response ( e.g . diabetes , porphyria ) . History significant dermatologic cancer ( e.g . melanoma , squamous cell carcinoma ) , except basal cell carcinomas superficial involve investigative site . Medical history hepatic disease Within three week prior dose , use medication treatment would significantly influence exaggerate response test product would alter inflammatory immune response product ( e.g . cyclosporine , tacrolimus , systemic topical corticosteroid , cytotoxic drug , immune globulin , Bacillus CalmetteGuerin , monoclonal antibody , radiation therapy ) . Within 72 hour prior dose , use antihistamine use topical drug patch site . Subject obvious difference skin color arm presence skin condition , excessive hair application site , scar tissue , tattoo , coloration would interfere placement test article , skin assessment , reaction drug . Presence open sore application site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Skin Diseases , Erythema</keyword>
</DOC>